Crinetics Pharmaceuticals Inc. (CRNX)
$84.46
$0.10
(0.12%)
As on 12-Aug-2026 16:01EDT
Market cap
$8,920 Mln
Revenue (TTM)
$42 Mln
P/E Ratio
--
P/B Ratio
6.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-13.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-5.1
-
Face value
--
-
Shares outstanding
106,095,205
8 Years Aggregate
CFO
$-512.91 Mln
EBITDA
$-665.32 Mln
Net Profit
$-645.89 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Crinetics Pharmaceuticals (CRNX)
| 81.4 | 1.1 | 131.1 | 208.5 | 72.3 | 34.6 | -- |
|
BSE Sensex*
| -7.9 | 0.5 | 4.5 | -2.9 | 6.1 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Crinetics Pharmaceuticals (CRNX)
| -9.0 | 43.3 | 94.4 | -35.6 | 101.3 | -43.8 | -16.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Crinetics Pharmaceuticals (CRNX)
|
84.5 | 8,920.5 | 42.2 | -501.6 | -1,217.0 | -45.9 | -- | 6.9 |
| 87.3 | 12,381.0 | 669.5 | -320.0 | -0.8 | -68.2 | -- | 26.6 | |
| 75.6 | 10,421.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 50.4 | 13,397.6 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 101.8 | 12,231.4 | 1,663.7 | 413.6 | 18.8 | 430 | 36.2 | 45.0 | |
| 332.9 | 9,662.5 | 440.5 | 241.5 | 33.4 | 18.7 | 41 | 7.0 | |
| 536.2 | 11,784.0 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.7 | |
| 597.0 | 16,486.6 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.4 | 37.6 | |
| 386.3 | 10,057.6 | 0.0 | -339.1 | -- | -30.6 | -- | 6.1 | |
| 152.0 | 9,439.0 | 282.0 | 82.9 | -28.6 | 11.4 | 143 | 11.2 |
Shareholding Pattern
View DetailsAbout Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product... candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Read more
-
Founder, President, CEO & Director
Dr. R. Scott Struthers Ph.D.
-
Founder, President, CEO & Director
Dr. R. Scott Struthers Ph.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Crinetics Pharmaceuticals (CRNX)
What is the current share price of Crinetics Pharmaceuticals Inc (CRNX) Today?
The share price of Crinetics Pharmaceuticals Inc (CRNX) is $84.46 (NASDAQ) as of 12-Aug-2026 16:01 EDT. Crinetics Pharmaceuticals Inc (CRNX) has given a return of 72.29% in the last 3 years.
What is the current PB & PE ratio of Crinetics Pharmaceuticals Inc (CRNX)?
Since, TTM earnings of Crinetics Pharmaceuticals Inc (CRNX) is negative, P/E ratio is not available.
The P/B ratio of Crinetics Pharmaceuticals Inc (CRNX) is 6.90 times as on 07-Aug-2026, a 30 premium to its peers’ median range of 5.32 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-9.41
|
4.41
|
|
2024
|
-15.68
|
3.53
|
|
2023
|
-11.14
|
4.43
|
|
2022
|
-6.16
|
3.11
|
|
2021
|
-12.04
|
3.87
|
What is the 52 Week High and Low of Crinetics Pharmaceuticals Inc (CRNX)?
The 52-week high and low of Crinetics Pharmaceuticals Inc (CRNX) are Rs 84.54 and Rs 27.52 as of 13-Aug-2026.
What is the market cap of Crinetics Pharmaceuticals Inc (CRNX)?
Crinetics Pharmaceuticals Inc (CRNX) has a market capitalisation of $ 8,920 Mln as on 07-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Crinetics Pharmaceuticals Inc (CRNX)?
Before investing in Crinetics Pharmaceuticals Inc (CRNX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.